Targets › INS
9 programs from 9 companies in 11 trials: 5 Phase 1, 3 Phase 2, 2 Phase 4, 1 Phase 3; Metabolic and endocrine, Gastroenterology, Neurology; next expected readout Dec 2026.
Hormone secreted by pancreatic islet beta cells, that is the principal anabolic regulator of glucose, lipid, and protein metabolism and the central controller of blood glucose homeostasis. Acts by binding to and activating the insulin receptor INSR, a receptor tyrosine kinase, triggering INSR autophosphorylation and recruitment/phosphorylation of insulin receptor substrate proteins IRS1 and IRS2, which activate the…. (UniProt, P01308)
Open in Phaseline: the race on INS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Campania Luigi Vanvitelli | Insulin pump (CSII: Continuous subcutaneous insulin infusion) Continuous subcutaneous delivery of rapid-acting insulin lispro as basal rate and boluses | INS | Phase 4 | Type 1 Diabetes Mellitus | Dec 2026 |
| Al-Shifa Trust Eye Hospital | Topical insulin eye drops Growth factor/neurotrophic factor for corneal epithelial repair | INS | Phase 4 | Persistent Corneal Epithelial Defect | – |
| Elgan Pharma | ELGN-2112 Human insulin [rDNA] | INS | Phase 3 | Intestinal Malabsorption | Jun 2027 |
| Gateway Institute for Brain Research | INS-GSH Intranasal insulin and glutathione combination | INS, GSS | Phase 2 | Parkinson Disease | Sep 2027 |
| Ain Shams University | Insulin producing stem cells Differentiated mesenchymal stem cells producing insulin and c-peptide | INS | Phase 2 | Stem Cells | – |
| Shifa International Hospital | Insulin Isophane Human, NPH, Pre-emptive Algorithm Insulin replacement therapy; neutral protamine Hagedorn (NPH) formulation for intermediate | INS | Phase 1 | Diabetes Mellitus, Type 2 | Jan 2027 |
| Gan & Lee Pharmaceuticals. | GZR33 Long-acting basal insulin analogue | INS | Phase 1 | Type 1 Diabetes Mellitis | – |
| Shanghai Jiao Tong University School of Medicine | Human insulin enteric coated capsules 16mg Oral recombinant human insulin via enteric coating | INS | Phase 1 | Diabete Mellitus | – |
| Portal Diabetes | Portal Insulin U-500 (PI-U500) Insulin analog | INS | Phase 1 | Type 1 Diabetes | – |
Intestinal Malabsorption (2) Diabete Mellitus (2) Stem Cells (1) Parkinson Disease (1) Diabetes Mellitus, Type 2 (1) Type 1 Diabetes Mellitis (1) Type 1 Diabetes Mellitus (1) Persistent Corneal Epithelial Defect (1) Type 1 Diabetes (1)
small molecule (3), protein or peptide (3), mixed (2), other (1)
Elgan Pharma (1) Ain Shams University (1) Gateway Institute for Brain Research (1) Shifa International Hospital (1) Gan & Lee Pharmaceuticals. (1) University of Campania Luigi Vanvitelli (1) Shanghai Jiao Tong University School of Medicine (1) Al-Shifa Trust Eye Hospital (1) Portal Diabetes (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.